CannBioRx Life Sciences C... (ATNFW)
0.01
0.00 (26.58%)
At close: Apr 21, 2025, 3:44 PM
Company Description
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University.
The company was founded by Marc Feldmann, Lawrence J.
Steinman, and Jonathan B.
Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.
CannBioRx Life Sciences Corp.
| Country | United States |
| IPO Date | n/a |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Lloyd Blair Jordan L.L.B., M.B.A. |
Contact Details
Address: Building 4 Palo Alto, Delaware United States | |
| Website | http://www.180lifesciences.com |
Stock Details
| Ticker Symbol | ATNFW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001690080 |
| CUSIP Number | n/a |
| ISIN Number | US68236V1127 |
| Employer ID | 81-3832378 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lloyd Blair Jordan L.L.B., M.B.A. | Chief Executive Officer & Director |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder & Director |
| Eric R. Van Lent | CAO, Principal Accounting & Financial Officer |
| Prof. Jagdeep Nanchahal M.D., Ph.D. | Co-Founder & Chairman of Clinical Advisory Board |
| Sir Marc Feldman Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | SCHEDULE 13G | Filing |
| Apr 11, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Apr 11, 2025 | 4 | Filing |
| Apr 09, 2025 | 8-K | Current Report |
| Apr 02, 2025 | 4 | Filing |
| Apr 01, 2025 | 8-K/A | [Amend] Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | SCHEDULE 13D | Filing |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 3 | Filing |